299 related articles for article (PubMed ID: 18791324)
1. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
2. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
4. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
5. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
7. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels.
Shimazu S; Shimatsu A; Yamada S; Inoshita N; Nagamura Y; Usui T; Tsukada T
Eur J Endocrinol; 2012 Mar; 166(3):383-90. PubMed ID: 22127489
[TBL] [Abstract][Full Text] [Related]
8. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
9. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
10. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
[TBL] [Abstract][Full Text] [Related]
12. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
13. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
[TBL] [Abstract][Full Text] [Related]
14. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
15. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
16. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.
Filopanti M; Lania AG; Spada A
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):43-53. PubMed ID: 19929252
[TBL] [Abstract][Full Text] [Related]
18. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.
Recouvreux MV; Camilletti MA; Rifkin DB; Díaz-Torga G
J Endocrinol; 2016 Mar; 228(3):R73-83. PubMed ID: 26698564
[TBL] [Abstract][Full Text] [Related]
19. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
Musolino NR; Passos VQ
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of difficult to treat macroprolactinomas.
Sahakian N; Castinetti F; Dufour H; Graillon T; Romanet P; Barlier A; Brue T; Cuny T
Expert Rev Endocrinol Metab; 2019 May; 14(3):179-192. PubMed ID: 30913932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
